Press Releases

Oasmia postpones the release of the Q4 and year-end report to 28 June

The Board of Oasmia has decided to postpone the release of the fourth quarter and year-end 2018/2019 report from 5 June 2019 to 28 June 2019. The delay is a result of the ongoing review initiated by the new Boa...

Oasmia expands the Management Team

Oasmia Pharmaceutical AB (NASDAQ: OASM) expands the Management Team in order to directly involve the whole organization in the commercialization of Apealea and other product candidates. Earlier the Management Team was...

Short report of the status of the review in Oasmia

Two weeks ago, March 19th, the Extra General Meeting in Oasmia elected a new Board on the initiative of the main owner Arwidsro. The new Board has since then taken control over the Company and started implemen...

Increase in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

The number of shares and votes in Oasmia Pharmaceutical AB (publ) has increased as a result of the directed new share issue carried out in March 2019. Through the directed share issue the number of outstanding shares and...

The results from Oasmia Pharmaceuticals first study with paclitaxel micellar in humans are published in the scientific journal ”Advances in Therapy”.

The study (OAS-04-01) was a tolerance and pharmacokinetic study where the dose for Apealea (paclitaxel micellar) was determined. This phase I study was conducted at two clinics in Sweden located in Lund and Umeå between...

Notification from Oasmia Pharmaceutical AB

Uppsala, Sweden, March 26, 2019 – The Swedish Securities Council has today published a statement regarding Oasmia. For statement please click here (...

CFO of Oasmia, Anders Blom has resigned

Yesterday Oasmia received the resignation of the Company’s CFO Anders Blom. The Board and the CEO have decided to appoint, as acting CFO, Joakim Lindén. Joakim Lindén has long experience from transition processes in ...

Oasmia Pharmaceutical AB receives positive opinion from the European Medicines Agency to add efficacy data to the approved Apealea® product information

Uppsala, Sweden, March 25, 2019 – Oasmia Pharmaceutical AB (NASDAQ: OASM) today announce that the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a type II variation application ...

New Board starts reviewing the situation in Oasmia

March 19th, the Extra General Meeting in Oasmia elected a new Board on the initiative of the main owner Arwidsro. The EGM was well represented with over a hundred participating shareholders and over 400 proxies. J...

Oasmia Pharmaceutical AB (publ): Press release from the extraordinary general meeting 19 March 2019

In Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) an extraordinary general meeting was held today. The extraordinary general meeting was convened at the request of shareholders representing more than...